Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Ken W who wrote (29232)	11/14/2002 12:29:57 PM
From: Ditchdigger	Read Replies (1) \| Respond to of 29382

tooks some 8% EDS profits at 14.93...bird in the hand (even if a small<g>)

To: Ken W who wrote (29232)	11/14/2002 12:30:28 PM
From: arnold silver	Respond to of 29382

Hi Ken, Sorry I couldn't get a link, This one looks like a good shot. financed by MO. Philip Morris and Endovasc Team Up to Further Improve Angiogenix; Nicotine-Based Treatment That Grows New Heart Vessels MONTGOMERY, Texas--(BUSINESS WIRE)--Nov. 6, 2002--Endovasc Ltd. Inc. (OTCBB:ENVC) -- a biotechnology company with two cardiovascular drugs approved for final FDA Phase III human trials - announced today that Philip Morris (NYSE:MO) and Endovasc have signed an agreement according to which Philip Morris has extended a grant for a one-year period to further study the potential for broad practical use of Endovasc's nicotine-based heart treatment, Angiogenix(TM). Angiogenix(TM) -- already approved for Phase III FDA human clinical trials - is a revolutionary new cardiovascular drug that has been proven to recruit the body's own stem cells that help grow new heart vessels predicted to relieve chest pain and improve heart function. Angiogenix(TM) is a simple, small molecule derived from the tobacco plant that, when given in low doses, has demonstrated remarkable results in stimulating robust growth of new vessels in four different animal experiments with simulated blood-flow deficiencies, suggesting that it will do the same in a human patient's heart and limbs. The treatment was originally developed by Stanford University, which licensed it to Endovasc on exclusive basis. In the most recent animal tests at Columbia University, all five of five mini swine tested demonstrated signs of new renewed blood flow. The study proved that Angiogenix(TM) is a safe treatment and works much better than anything else on the horizon for angiogenesis - with the potential of becoming a biological alternative to a by-pass surgery. For more information on the study, visit biz.yahoo.com The most recent research results were publicized in accordance with rules regarding publications and presentations during an oral presentation at the recent 49th Annual World Wide Conference of the American College of Angiology (ACA) in Maui, Hawaii where Endovasc CEO, Dr. David P. Summers, PhD, FACA presented a summary of the results of animal experiments to date. In a lively discussion regarding the therapeutic benefits of low-dose nicotine, Dr. Robert B. Kalmansohn, Past President and Emeritus Professor of Clinical Medicine and Cardiology at UCLA and Attending Physician at Cedars Sinai Hospital in Los Angeles commented, " Regardless of its origins, if this potential therapy continues to demonstrate safety and efficacy as it has demonstrated in the animal model it may become one of the greatest benefits to cardiovascular disease in the 21st century." "Philip Morris' continuous support will be instrumental in making Angiogenix(TM) available for broad clinical application," says Dr. David P. Summers, Chairman and Chief Executive Officer of Endovasc. "With their financial help, Endovasc may be able to move beyond the special equipment use available only in large specialized institutions to a much broader clinical use of this therapy, making Angiogenix(TM) available to every interventional cardiologist, interventional radiologist, neurologist, and vascular surgeon who are trained in use of catheters and stent placement in their practice. Getting beyond expensive intra-cavity injection systems would make the therapy potentially available to millions of additional patients in most every part of the world." Endovasc's current FDA Phase III approval requires the use of special heart mapping equipment only available in a few select hospitals in the world. "This is a good start," says Summers. "If the treatment works as it now appears it will, the therapy deserves utilization by the practicing specialist in small to medium-sized hospitals all around the world who do not have access to expensive equipment." Endovasc plans to begin experiments that allow the blood-vessel growing drug to be released from vascular stents, which could be placed deep in the feeding artery that leads to the blood-starved area, which often develops after heart attack or various heart diseases. Philip Morris has been financially supporting Endovasc's research since 2000. Endovasc's ANGIOGENIX(TM) treatment is currently the only viable angiogenesis treatment approved for Phase III trials. The company is well ahead of all other biotech firms in bringing an angiogenesis drug to the market. The company's larger competitors, Genentech (NYSE:DNA - News) and Genzyme (Nasdaq:GENZ) are still in Phase II trials with their angiogenesis treatments and are experiencing various challenges, whereas Endovasc's treatment has already been approved for FDA Phase III human clinical trials. Arnie